This $5B Pharmaceutical Could Benefit From Over-The-Counter Contraceptives And Plan B Alternatives

Zinger Key Points
  • The analyst cites Perrigo as a possible benefactor of the Supreme Court ruling thanks to a switch to over-the-counter initiatives.
  • Perrigo acquired HRA Pharma in May 2022 and the analyst points to this acquired company as being overlooked by investors.
This $5B Pharmaceutical Could Benefit From Over-The-Counter Contraceptives And Plan B Alternatives

The ruling by the U.S. Supreme Court to overturn Roe v. Wade and leave the decision of abortion to the states has been a big topic over the last few days. An analyst singles out a pharmaceutical company that could benefit from increased purchases of over-the-counter contraceptives.

The Perrigo Analyst: Raymond James analyst Elliot Wilbur has an Outperform rating on Perrigo Company PRGO.

The Analyst Takeaways: Wilbur cites Perrigo as a possible benefactor of the Supreme Court ruling thanks to a switch to over-the-counter initiatives the company has made.

Related Link: 3 Women's Health Stocks Are Soaring Following Roe V. Wade Ruling 

“PRGO should be at the forefront of any discussions regarding potential financial beneficiaries from changes in the reproductive health landscape that will likely emerge from the ruling,” Wilbur said.

Perrigo acquired HRA Pharma in May 2022 and the analyst points to this acquired company as being overlooked by investors. HRA is expected to file an application for an over-the-counter daily birth control pill by the end of 2022, the analyst noted.

Over-the-counter contraception is a market worth $5.5 billion in the U.S. with oral contraceptives worth $2.8 billion.

The analyst sees Perrigo being able to get a piece of this market that belongs to large pharmaceutical companies with the new HRA Pharma drug.

“While total contraceptive usage is almost certain to increase, we believe the total volume lift will be marginal.”

An over-the-counter option could increase accessibility in both cost and to women who don’t want to speak to a doctor about their birth control options.

The analyst sees potential annual sales of the HRA pill hitting $100 million to $200 million based on 50 cents per pill as the cost and hitting 5% to 10% of the contraceptive market.

Emergency contraceptive usage could go up after the ruling, Wilbur adds. The HRA acquisition also gave Perrigo ownership of Ella, a prescription-based emergency contraceptive. Ella is effective up to five days after unprotected sex.

“Ella could continue to benefit from an overall lift in emergency contraceptives even at the Rx level based on increased ‘just in case’ co-prescribing with standard oral contraceptive regimens.”

PRGO Price Action: Perrigo shares closed up 0.95% to $41.57 on Monday versus a 52-week range of $31.32 to $50.89.

See Also: Supreme Court Overturns Roe V. Wade 

Photo: Reproductive Health Supplies Coalition on Unsplash

 

Posted In: contraceptivesElliot Wilburover-the-counterpharmaceutical stocksPlan BRaymond JamesRoe v. WadeStocks To WatchSupreme CourtUS Supreme CourtAnalyst ColorNewsAnalyst Ratings

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.